Cellomatics Biosciences, a Nottingham-based preclinical contract research organisation, continues to expand its global client base by adding two new members of staff to support its business development efforts.
The company has welcomed Dr Pier Giorgio Amendola and Dr Jyoti Mundra to assist the company with its expansion into both European and US markets.
A key challenge for UK-based CROs operating internationally is managing cultural differences and regional market dynamics. Pier will use his experience to navigate these challenges in European markets and build strong local partnerships. He…
Three innovative R&D companies have expanded into the state-of-the-art Hexagon Tower in Blackley, signalling a growing interest in science infrastructure outside of Manchester city centre, according to site operator Pioneer Group.
Hexagon Tower, part of Pioneer Group’s wider life sciences network that includes 645 R&D businesses across Europe, is a significant R&D landmark in Manchester, located next to North Manchester General Hospital (NMGH).
Designed by the renowned modernist architect Richard Seifert, the 11 floor, 165,000 sq ft building opened in 1973 and has become one of…
Press release
Macomics Team Scores Gold and Raises Over £600 in its Hyper-Triathlon Challenge in aid of Founder Prof. Jeffrey Pollard’s Memorial Fund
Edinburgh and Cambridge, UK, 12 August 2024 – With Olympics drawn to a close, the team at Macomics Ltd, a leader in macrophage drug discovery, is celebrating its own achievement in raising over £600 in its Hyper-Triathlon Challenge. Started in 2023 in honour of its late co-founder Prof. Jeffrey Pollard, the Challenge set out to raise funds for the charity established as a memorial in his name, now renamed the Jeffrey and Ooi Thye Pollard fund.…
Read August eNews here
Featuring:
✅ Tony Jones, CEO, One Nucleus monthly news✅ Could CRISPR Bridge Sustainability and Life Sciences?✅ Boston and Beyond✅ A Deep Dive into Deepfakes✅ Oxford-Cambridge Supercluster Launches Policies to Kickstart Knowledge Intensive Economic Growth✅ The East of England: a Life Science Region Primed for Growth✅ EY ITEM Club Summer Forecast✅ Recording and Q&A Webinar: ‘In Vitro Assessment of Cardiac Risk in Drug Discovery’ BY Metrion Biosciences✅ Maximise Your Presence at BIO-Europe
AMSBIO has published an informative online article that reviews the importance of culture techniques for induced pluripotent stem cells (iPSCs), which provide an invaluable resource for drug discovery and therapeutic applications.
When using iPSCs for drug discovery and therapeutic applications, it is vital to generate a homogenous culture. The absence of uniformity in iPSC culture can severely compromise the quality and quantity of data generated.
The article discusses in detail how factors including maintaining genetic stability, optimizing culture conditions, and managing single…
Agreement builds on and complements Daiichi Sankyo and MSD’s shared commitment to develop novel medicines for patients with cancer
Daiichi Sankyo and MSD to co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where MSD retains exclusive rights
TOKYO & RAHWAY, N.J., August 6, 2024 – Daiichi Sankyo (TSE: 4568) and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) (NYSE: MRK) have expanded their existing global co-development and co-commercialization agreement for three investigational DXd…
Sandwich, Kent, UK / 6th August 2024 / Asymchem Laboratories (Tianjin) Co., Ltd. has officially inaugurated its new European development and pilot manufacturing site at Discovery Park in Sandwich, Kent, U.K., marked with a ribbon cutting on Friday 2 August by Dr. Hao Hong, Chairman, Founder, and CEO of Asymchem.
The former Pfizer small molecule facilities now employ 70 team members on-site in both the R&D labs and the API pilot plant, many of whom are legacy Pfizer employees. Additional hires are planned through to the end of the year as the pilot plant ramps up operations.
Building on a…
KISS is conducting a 2-minute survey to gather insights on the integration and usage of AI in business and marketing operations across different sectors including, Science, Technology, Education, Agriculture and Professional Services.
We are looking to help identify industry trends, support needs, and guide innovation and anonymised results will be shared with all participants.
Fill out the survey here.
Questions we are asking include:
What kind of training would be most beneficial for your organisation regarding AI and AI tools?
What are your primary concerns or worries regarding the use of…
Continuous 2 is an active project aiming to address the growing demand for cost-effective biologics treatments. With the global biopharmaceutical market estimated to grow to 3.9bn by 2024, the industry must act quickly to make these life-changing drugs more accessible to patients, and respond to the demand for flexible manufacturing technology that delivers real-time release of biotherapeutics.
UK Continuous 2 is building on the achievements of two previous projects:
UK Integrated Continuous Bioprocessing project 2020: this project established an integrated continuous downstream manufacturing…
The July edition of our People Pathways newsletter is now available to read here. You can read about:✴ New and upcoming One Nucleus courses✴ Registration open for the next BLSA SIG webinar✴ Reflections and takeaways from our Neurodiversity webinar✴ New mentoring opportunitiesand more...